Premium
Topical treatment of psoriatic plaques with 1,25‐dihydroxyvitamin D 3 : a cell biological study
Author(s) -
GERRITSEN M.J.P.,
RULO H.F.C.,
VLIJMENWILLEMS I.,
ERP P.E.J.,
KERKHOF P.C.M.
Publication year - 1993
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1993.tb00263.x
Subject(s) - medicine , calcitriol , dermatology , psoriasis , pathology , vitamin d and neurology
Summary Calcitriol, 1α,25 dihydroxycholecalciferol (α.25 (OH) 2 D 2 ) is a natural active vitamin D 3 metabolite, which has been shown to have antipsoriatic efficacy. In vitro studies have demonstrated that calcitriol influences various aspects of inflammation, epidermal proliferation and keratinization. The aim of the present study was to determine to what extent caicitriol (3 μ/g in white petrolatum) affects these parameters in vivo . Using an immunohistochemical assessment of recruitment of cycling epidermal cells, filaggrin and involucrin expression. T‐cell accumulation, polymorphonuclear neutrophil (PMN) accumulation, amount of endothelium and ICAM‐1 expression, we demonstrated that: (1) modulation of all these parameters occurred during calcitriol treatment; (ii) there was early reduction of epidermal proliferation and PMN accumulation: (iii) the order of changes was comparable with the response to treatment with calcipotriol. In conclusion, at the cell biological level, calcitriol (3 μ/g in white petrolatum) has a substantial effect on various elements of the psoriatic lesion.